{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T21:49:32Z","timestamp":1767908972690,"version":"3.49.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,9]]},"DOI":"10.7759\/cureus.91929","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T21:40:38Z","timestamp":1757454038000},"source":"Crossref","is-referenced-by-count":2,"title":["Real-World Evidence Demonstrating Nemolizumab's Rapid Efficacy in Recalcitrant Uremic Pruritus"],"prefix":"10.7759","author":[{"given":"Hunter","family":"Dalisay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harshitha","family":"Segabandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kostandin","family":"Valle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Tinker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.23876\/j.krcp.21.189","article-title":"Uremic pruritus: pathophysiology, clinical presentation, and treatments","volume":"42","author":"Ko MJ","year":"2023","unstructured":"Ko MJ, Peng YS, Wu HY. Uremic pruritus: pathophysiology, clinical presentation, and treatments. Kidney Res Clin Pract. 2023, 42:39-52. 10.23876\/j.krcp.21.189","journal-title":"Kidney Res Clin Pract"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01383","article-title":"Role of the pruritic cytokine IL-31 in autoimmune skin diseases","volume":"10","author":"Gibbs BF","year":"2019","unstructured":"Gibbs BF, Patsinakidis N, Raap U. Role of the pruritic cytokine IL-31 in autoimmune skin diseases. Front Immunol. 2019, 10:1383. 10.3389\/fimmu.2019.01383","journal-title":"Front Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2015.06.009","article-title":"Pruritus in kidney disease","volume":"35","author":"Combs SA","year":"2015","unstructured":"Combs SA, Teixeira JP, Germain MJ. Pruritus in kidney disease. Semin Nephrol. 2015, 35:383-91. 10.1016\/j.semnephrol.2015.06.009","journal-title":"Semin Nephrol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2020.155369","article-title":"Elevated interleukin 31 serum levels in hemodialysis patients are associated with uremic pruritus","volume":"138","author":"Oweis AO","year":"2021","unstructured":"Oweis AO, Al-Qarqaz F, Bodoor K, et al.. Elevated interleukin 31 serum levels in hemodialysis patients are associated with uremic pruritus. Cytokine. 2021, 138:155369. 10.1016\/j.cyto.2020.155369","journal-title":"Cytokine"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.638325","article-title":"Interleukin-31 as a clinical target for pruritus treatment","volume":"8","author":"Kabashima K","year":"2021","unstructured":"Kabashima K, Irie H. Interleukin-31 as a clinical target for pruritus treatment. Front Med (Lausanne). 2021, 8:638325. 10.3389\/fmed.2021.638325","journal-title":"Front Med (Lausanne)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301333","article-title":"Phase 3 trial of nemolizumab in patients with prurigo nodularis","volume":"389","author":"Kwatra SG","year":"2023","unstructured":"Kwatra SG, Yosipovitch G, Legat FJ, et al.. Phase 3 trial of nemolizumab in patients with prurigo nodularis. N Engl J Med. 2023, 389:1579-89. 10.1056\/NEJMoa2301333","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-021-02047-2","article-title":"Anti-pruritic effect of nemolizumab in hemodialysis patients with uremic pruritus: a phase II, randomized, double-blind, placebo-controlled clinical study","volume":"25","author":"Kinugasa E","year":"2021","unstructured":"Kinugasa E, Igawa K, Shimada H, et al.. Anti-pruritic effect of nemolizumab in hemodialysis patients with uremic pruritus: a phase II, randomized, double-blind, placebo-controlled clinical study. Clin Exp Nephrol. 2021, 25:875-84. 10.1007\/s10157-021-02047-2","journal-title":"Clin Exp Nephrol"},{"key":"ref8","unstructured":"NEMLUVIO\u00ae (nemolizumab-Ilto) for injection 30mg. (2024). Accessed. August 3, 2025: https:\/\/www.galderma.com\/sites\/default\/files\/2024-12\/Nemluvio_Dual%20PI%20for%20website%2013Dec24.pdf."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfab200","article-title":"Unravelling the pathophysiology of chronic kidney disease-associated pruritus","volume":"14","author":"Schricker S","year":"2021","unstructured":"Schricker S, Kimmel M. Unravelling the pathophysiology of chronic kidney disease-associated pruritus. Clin Kidney J. 2021, 14:i23-31. 10.1093\/ckj\/sfab200","journal-title":"Clin Kidney J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/toxins14030197","article-title":"The serum level of IL-31 in patients with chronic kidney disease-associated pruritus: what can we expect?","volume":"14","author":"\u015awierczy\u0144ska K","year":"2022","unstructured":"\u015awierczy\u0144ska K, Krajewski PK, Nowicka-Suszko D, Bia\u0142ynicki-Birula R, Krajewska M, Szepietowski JC. The serum level of IL-31 in patients with chronic kidney disease-associated pruritus: what can we expect?. Toxins (Basel). 2022, 14:10.3390\/toxins14030197","journal-title":"Toxins (Basel)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2018.10.001","article-title":"The itch-scratch cycle: a neuroimmune perspective","volume":"39","author":"Mack MR","year":"2018","unstructured":"Mack MR, Kim BS. The itch-scratch cycle: a neuroimmune perspective. Trends Immunol. 2018, 39:980-91. 10.1016\/j.it.2018.10.001","journal-title":"Trends Immunol"},{"key":"ref12","article-title":"Role of interleukin-31 and oncostatin M in itch and neuroimmune communication","author":"Cevikbas F","year":"2014","unstructured":"Cevikbas F, Kempkes C, Buhl T, Mess C, Buddenkotte J, Steinhoff M. Role of interleukin-31 and oncostatin M in itch and neuroimmune communication. Itch: Mechanisms and Treatment. Carstens E, Akiyama T (ed): CRC Press\/Taylor & Francis, Boca Raton; 2014."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.10.048","article-title":"A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1","volume":"133","author":"Cevikbas F","year":"2014","unstructured":"Cevikbas F, Wang X, Akiyama T, et al.. A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1. J Allergy Clin Immunol. 2014, 133:448-60. 10.1016\/j.jaci.2013.10.048","journal-title":"J Allergy Clin Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113433","article-title":"Sensory neuronal STAT3 is critical for IL-31 receptor expression and inflammatory itch","volume":"42","author":"Takahashi S","year":"2023","unstructured":"Takahashi S, Ochiai S, Jin J, et al.. Sensory neuronal STAT3 is critical for IL-31 receptor expression and inflammatory itch. Cell Rep. 2023, 42:113433. 10.1016\/j.celrep.2023.113433","journal-title":"Cell Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.2609","article-title":"Modulation of neuroimmune and epithelial dysregulation in patients with moderate to severe prurigo nodularis treated with nemolizumab","volume":"159","author":"Deng J","year":"2023","unstructured":"Deng J, Liao V, Parthasarathy V, et al.. Modulation of neuroimmune and epithelial dysregulation in patients with moderate to severe prurigo nodularis treated with nemolizumab. JAMA Dermatol. 2023, 159:977-85. 10.1001\/jamadermatol.2023.2609","journal-title":"JAMA Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/403163-real-world-evidence-demonstrating-nemolizumabs-rapid-efficacy-in-recalcitrant-uremic-pruritus","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T21:40:39Z","timestamp":1757454039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/403163-real-world-evidence-demonstrating-nemolizumabs-rapid-efficacy-in-recalcitrant-uremic-pruritus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.91929","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,9]]}}}